Story · Medicine & Biotech
FDA Slaps New Safety Warning on GLP-1 Drugs
38 outlets · first reported by FDA MedWatch Safety Alerts 4d ago · latest 6h ago · 98 hours of coverage · 10 countries
Coverage, in order
-
4d agoMedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
-
3d agoFDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition
FDA is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
-
3d ago
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionThe Food and Drug Administration on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharma companies to inform patients and doctors of the risk. The condition, called non-arteritic anterior ischemic optic neuropathy, or NAION, is sometimes…
-
3d agoU.S. regulators are requiring the makers of blockbuster drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss
The FDA is requiring the makers of drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss.
-
3d ago
FDA Slaps New Safety Warning on GLP-1 Drugs(MedPage Today) -- The FDA is requiring manufacturers of all GLP-1 drugs to update their prescribing information to include a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but potentially blinding...
-
3d ago
FDA requires new safety warnings for GLP-1 drugsThe FDA is now requiring labeling updates for all GLP-1 medications due to a risk of NAION, a rare eye condition that can result in sudden, permanent vision loss.
-
3d agoFDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition
Today, the U.S. Food and Drug Administration (FDA) announced that patients and healthcare providers should be aware of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION…
-
3d ago
FDA to require NAION risk warning for GLP-1 therapiesEditor’s note: This is a developing news story. Please check back soon for updates. The FDA is requiring manufacturers of GLP-1 receptor agonist therapies to include warnings regarding the risk for nonarteritic anterior ischemic optic neuropathy, according to a drug safety communication. The agency…
-
3d ago
FDA warns of rare 'eye stroke' risk from GLP-1 drugsThe Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior ischemic optic…
-
3d agoSafety and efficacy of oral non-peptide GLP-1 receptor agonist in non- diabetic obese patients; systematic review and meta-analysis of randomized controlled trials
Background Oral glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been developed as a needle-free alternative of subcutaneous injectables GLP-1 RAs. This systematic review and meta-analysis evaluated whether oral GLP-1 receptor agonists improve body weight and metabolic outcomes, and…
-
3d ago
Estados Unidos exige reforzar las advertencias sobre los riesgos oculares asociados a los fármacos GLP-1La FDA apunta a los peligros de Ozempic, Wegovy y Foundayo, entre otros Y además: El fabricante de Wegovy busca "la forma más sostenible" de integrar su fármaco en la sanidad pública española
-
3d agoFDA orders blindness risk warning to GLP-1 agonist labels
FDA orders blindness risk warning to GLP-1 agonist labels Phil.Taylor Tue, 10/11/2026 - 10:49
-
3d agoUS requires vision-loss warning on Ozempic and Mounjaro labelsEUA exigem alerta de risco de perda de visão nas bulas de Ozempic e Mounjaro
A FDA , agência reguladora de medicamentos dos Estados Unidos, determinou que os fabricantes de agonistas de GLP-1 ( canetas emagrecedoras ), como Ozempic, Wegovy e Mounjaro, incluam nas bulas alertas sobre aumento de risco de uma condição ocular grave associada ao uso dos medicamentos. Leia mais…
-
3d agoFDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
-
2d ago
FDA warns of eye risk from GLP-1 drugsFDA с предупреждение за риск за очите от пептидиТе се отнасят за употребата на медикаментите Ozempic и Zepbound, станали особено популярни за отслабване
-
2d ago
FDA warns of possible eye risks with Ozempic and other GLP-1 drugsLa FDA alerta sobre posibles riesgos oculares asociados a Ozempic y otros medicamentos GLP-1La advertencia incluye medicamentos utilizados para tratar la diabetes tipo 2 y la obesidad. Piden prestar atención a cambios repentinos en la visión.
-
2d ago
STAT+: GLP-1s are given an FDA warning for rare eye condition riskWant to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news that we’ll get straight into. The need-to-know this morning Beam Therapeutics said its CRISPR-based treatment for sickle cell disease…
-
2d agoFDA inclui alerta sobre perda de visão rara em medicamentos populares da classe GLP-1
Medicamentos populares para perda de peso, incluindo Ozempic e Wegovy, passarão a trazer um novo alerta sobre um possível efeito colateral raro que, em alguns casos, pode levar à perda permanente da visão, anunciaram as autoridades de saúde dos Estados Unidos nesta segunda-feira (9). A Food and…
-
2d agoFDA: Έκτακτη οδηγία για τα φάρμακα αδυνατίσματος λόγω πιθανής βλάβης στην όραση – Να να αναγράφονται οι προειδοποιήσεις
Τι αποκαλύπτει η αξιολόγηση σε 134.000 ασθενείς για τη σπάνια πάθηση NAION, ποια δημοφιλή σκευάσματα επηρεάζονται και τι ισχύει στην Ευρώπη
-
2d ago
'Ozempic made me go suddenly blind': Victim reveals devastation after losing his sight on the jabs as US health chiefs order new warning over 'eye stroke' vision loss riskIt was Christmas Day two years ago when Jay Vandegriff noticed a smudge on his glasses which obscured his left eye.
-
2d ago
USFDA Flags Potential Vision Loss Risk with Ozempic, Wegovy, Mounjaro, Seeks Label Warning UpdateBengaluru : The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. The US Food and Drug Administration said it is requiring GLP-1 drugs such as Eli Lilly's…
-
2d ago
FDA Initiates Labeling Changes for GLP-1s Due to Rare But Serious Eye Disease RiskA rare eye disease has been added to the growing list of side effects linked to GLP-1s, adding a second eye warning to several labels. Michael Siluk/UCG/Universal Images Group via Getty Images The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a…
-
2d agoFDA Mandates Label Updates for GLP-1 Receptor Agonists Over Eye Risk
A new safety communication highlights a potential increased risk of a rare but serious eye condition associated with a popular class of medications. Key takeaways: The FDA is requiring safety labeling changes for all GLP-1 receptor agonist medications to include warnings about a potential increased…
-
2d ago
FDA Requires GLP-1s to Carry Warning About Rare Risk of Vision LossThe U.S. Food and Drug Administration (FDA) announced this week that it is requiring manufacturers of all GLP-1 diabetes and obesity medications to make labeling changes that will warn patients about the increased risk of a rare eye condition linked to these…
-
2d ago
Rare eye condition prompts new FDA warning on popular GLP-1 drugsThe U.S. Food and Drug Administration (FDA) is requiring makers of Ozempic, Wegovy and similar drugs to warn of a rare eye condition that can cause vision loss.
-
2d agoUS FDA mandates optic neuropathy warning on all GLP-1 products美 FDA, GLP-1 계열 전제품에 '시신경병증' 경고 의무화
미국 식품의약국(FDA)이 지난 9일(현지시각) GLP-1 계열 의약품에 비동맥염성 전방 허혈성 시신경병증(NAION) 초래 가능성 표기를 의무화했다. 이와 관련해 식품의약품안전처는 GLP-1 계열 의약품의 허가변경 등을 검토한다는 방침이다.나이온(NAION)은 시신경 혈류 차단으로 인해 급격한 시력 저하가 나타나는 증상이다. 급성·무통성 시력 저하 또는 영구적 시력 상실 등을 초래할 수 있다.FDA는 이날 공식 홈페이지를 통해 GLP-1 계열 의약품 허가권자(제약사)가 NAION의 잠재적 위험 증가에 대한 정보를 제품 내 첨부문서
-
2d ago
GLP-1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effectMillions of people worldwide take GLP-1 medications. Michael Siluk/Universal Images Group via Getty Images GLP-1 drugs must now carry a warning label about a potential link to a rare eye condition that can result in vision loss, the U.S. Food and Drug Administration announced on Nov. 9. 2026. The…
-
2d agoRare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide
Nature Metabolism, Published online: 11 November 2026; doi:10.1038/s42255-026-01656-z Rare GLP1R variants are shown to reduce weight loss with semaglutide but not tirzepatide, suggesting GLP1R genetic variation as a pharmacogenetic determinant of GLP-1 receptor agonist efficacy.
-
2d agoGreek medicines agency reassures on GLP-1 drugs and the rare optic neuropathy riskΕΟΦ: Καθησυχαστικός ο Σπύρος Σαπουνάς για τα φάρμακα GLP-1 και τον σπάνιο κίνδυνο οπτικής νευροπάθειας
Τα πρόσφατα δημοσιεύματα για πιθανή σύνδεση των φαρμάκων GLP-1 με σοβαρές οφθαλμολογικές επιπλοκές έχουν προκαλέσει ανησυχία σε χιλιάδες ασθενείς με διαβήτη και παχυσαρκία. Ο πρόεδρος του ΕΟΦ, Σπύρος Σαπουνάς , καλεί το κοινό να αξιολογήσει τα επιστημονικά δεδομένα με ψυχραιμία και να μην προχωρά…
-
2d ago
Side effects of the 'Ozempic family': FDA requires a warning about optic neuropathyEfectos secundarios de la 'familia Ozempic': la FDA exige avisar sobre el riesgo de desarrollar neuropatía ópticaEl pasado lunes, la Administración de Alimentos y Medicamentos de EEUU (FDA, por sus siglas en inglés) informó a los pacientes y a los profesionales sanitarios sobre un posible aumento del riesgo de padecer una afección ocular grave asociada al uso de fármacos agonistas del receptor de GLP-1 …
-
1d ago
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warningThe deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
-
1d agoGLP-1: package warning that the drug may cause a rare eye conditionGLP-1: Οδηγία στη συσκευασία ότι το φάρμακο μπορεί να προκαλέσει σπάνια πάθηση στα μάτια
Ενδέχεται να προκαλέσει αιφνίδια τύφλωση, σύμφωνα με τους υπεύθυνους του αμερικανικού Οργανισμού Φαρμάκων (FDA).
-
1d agoGLP-1: packaging to warn of a rare eye conditionGLP-1: Προειδοποίηση στη συσκευασία ότι το φάρμακο μπορεί να προκαλέσει σπάνια πάθηση στα μάτια
Ενδέχεται να προκαλέσει αιφνίδια τύφλωση, σύμφωνα με τους υπεύθυνους του αμερικανικού Οργανισμού Φαρμάκων (FDA).
-
1d ago
Ozempic, Wegovy and other obesity drugs under watch for a possible serious eye effectOzempic, Wegovy y otros medicamentos contra la obesidad, bajo vigilancia por un posible efecto ocular graveFDA alert.La Administración de Alimentos y Medicamentos de Estados Unidos (FDA) ha alertado de un posible aumento del riesgo de sufrir una enfermedad ocular grave entre las personas que utilizan medicamentos agonistas del receptor GLP-1, empleados para tratar la diabetes tipo 2 y la obesidad. La agencia…
-
1d ago
Qual é o risco de doença grave nos olhos por uso de Ozempic e Mounjaro que gerou alerta de agência dos EUAozempic Getty Images/BBC A FDA, agência reguladora de medicamentos dos Estados Unidos, determinou que os fabricantes de canetas para perda de peso da classe dos agonistas de GLP-1 devem incluir em suas bulas alertas sobre aumento de risco de uma condição ocular grave associada ao uso dos…
-
1d agoΗ ανακοίνωση του ΕΟΦ για GLP-1 και προβλήματα όρασης – Τι να ξέρουν όσοι τα λαμβάνουν
Στην ανησυχία που έχουν προκαλέσει σε πολλούς ασθενείς τα πρόσφατα δημοσιεύματα για πιθανή σύνδεση των ενέσιμων φαρμάκων για τον διαβήτη και την απώλεια βάρους με μια σπάνια πάθηση του οπτικού νεύρου απαντά ο πρόεδρος του Εθνικού Οργανισμού Φαρμάκων (ΕΟΦ), κ. Σπύρος Σαπουνάς . Σε ανάρτησή του, ο…
-
1d ago
Could Your GLP-1s Make You Blind? Here’s What to Make of the FDA’s Latest Notice.Doctors don’t want you to panic.
-
1d ago
-
1d agoFDA requires vision-loss warning on drugs such as Ozempic and WegovyFDA exige alerta sobre perda de visão em medicamentos como Ozempic e Wegovy
Diabetes and weight-loss drugs will carry new label warnings.Os medicamentos indicados para a diabetes e para a perda de peso, como o Ozempic e o Wegovy, vão passar a ter nos Estados Unidos um alerta sobre um efeito secundário raro que pode levar à perda de visão. O anúncio foi feito pelas autoridades sanitárias norte-americanas, que decidiram estender o…
-
21h ago
Could Your GLP-1s Make You Blind? Here’s What to Make of the FDA’s Latest Notice.
Doctors don’t want you to panic.
-
21h ago
NAION: o que é a doença ocular rara associada a medicamentos como Ozempic que pode causar perda súbita da visãoDoença ocular grave foi associada ao uso de canetas emagrecedoras
-
16h ago
How Much Fiber Do You Need on a GLP-1?Why Fiber Is Crucial Why Fiber Is Crucial While Taking a GLP-1 Fiber matters if you’re on a GLP-1 because of how these medications work . Semaglutide (Wegovy, Ozempic), orforglipron (Foundayo), and tirzepatide (Mounjaro, Zepbound) are copies of natural hormones produced by the intestines…
-
12h agoRare GLP1R variants diminish the weight loss effect of semaglutide but not of tirzepatide
Nature Metabolism, Published online: 13 November 2026; doi:10.1038/s42255-026-01661-2 In a large, real-world genomic study, rare damaging variants in the gene encoding the glucagon-like peptide 1 (GLP1) receptor blunted weight loss in people taking semaglutide but had no significant effect on…
-
8h agoOral GLP-1 Receptor Agonist Reduces OSA Severity in Phase 3 Trial
Positive results from the ATTAIN-OSA clinical program highlight the potential of a once-daily pill to reduce the AHI and improve cardiovascular risk factors in adults with obesity. Key takeaways: Eli Lilly’s phase 3 ATTAIN-OSA trial evaluated Foundayo (orforglipron), an oral GLP-1 receptor agonist…
-
8h agoSetting aside the glucose and weight 'report card': the era of integrated CKM care, and the role of GLP-1 drugs혈당·체중 '성적표' 내려놓을 때…CKM '통합 관리' 시대, GLP-1 역할은?
Diabetes consultations in Korea usually last about ten minutes.10분. 당뇨병 환자 진료에 주어지는 시간은 대개 이 정도다. 그 안에 의사와 환자는 지난 실패를 복기하고 성공을 향한 계획을 수정해야 한다. 당화혈색소(HbA1c)와 체중은 성공과 실패를 가르는 성적표다. 자연히 약의 이점도 '얼마나 빨리, 얼마나 많이'로 축소된다.한국과 미국의 진료를 모두 경험한 미국 하버드의대 매스 제너럴 브리검(Mass General Brigham) 내분비내과 강유미 교수는 최근 청년의사와 만난 자리에서 이런 진료실 풍경 자체를 바꿔야 한다고 했다. 질환의 수치를 "성적표처럼 다루고", 환자는 무엇을 위해
-
6h agoΦάρμακα GLP-1: Τι σημαίνει η νέα προειδοποίηση του FDA για την όραση
Προειδοποίηση για πιθανό αυξημένο κίνδυνο μιας σπάνιας αλλά σοβαρής πάθησης του οπτικού νεύρου, που μπορεί να απειλήσει την όραση , θα φέρουν στο εξής όλα τα φάρμακα της κατηγορίας GLP-1 , όπως η λιραγλουτίδη και η τιρζεπατίδη. Την απόφαση ανακοίνωσε στις 9 Νοεμβρίου ο αμερικανικός Οργανισμός…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.